TrialBlood cancer journal2022

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.

Holger W Auner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.